BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 21198717)

  • 1. Management of relapsed or refractory multiple myeloma in French hospitals and estimation of associated direct costs: a multi-centre retrospective cohort study.
    Armoiry X; Fagnani F; Benboubker L; Facon T; Fermand JP; Hulin C; Moreau P; Aulagner G
    J Clin Pharm Ther; 2011 Feb; 36(1):19-26. PubMed ID: 21198717
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of novel relapsed-refractory multiple myeloma therapies in Norway: lenalidomide plus dexamethasone vs bortezomib.
    Möller J; Nicklasson L; Murthy A
    J Med Econ; 2011; 14(6):690-7. PubMed ID: 21892856
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-world health care costs of relapsed/refractory multiple myeloma during the era of novel cancer agents.
    Gaultney JG; Franken MG; Tan SS; Redekop WK; Huijgens PC; Sonneveld P; Uyl-de Groot CA
    J Clin Pharm Ther; 2013 Feb; 38(1):41-7. PubMed ID: 23126374
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The cost-effectiveness of bortezomib in relapsed/refractory multiple myeloma: Swedish perspective.
    Hornberger J; Rickert J; Dhawan R; Liwing J; Aschan J; Löthgren M
    Eur J Haematol; 2010 Dec; 85(6):484-91. PubMed ID: 20846301
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Total cost comparison in relapsed/refractory multiple myeloma.
    Durie B; Binder G; Pashos C; Khan Z; Hussein M; Borrello I
    J Med Econ; 2013; 16(5):614-22. PubMed ID: 23281721
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pomalidomide in the treatment of relapsed multiple myeloma.
    Forsberg PA; Mark TM
    Future Oncol; 2013 Jul; 9(7):939-48. PubMed ID: 23837756
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel agents for relapsed and/or refractory multiple myeloma.
    Thomas SK; Richards TA; Weber DM
    Cancer J; 2009; 15(6):485-93. PubMed ID: 20010168
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Policymaker, please consider your needs carefully: does outcomes research in relapsed or refractory multiple myeloma reduce policymaker uncertainty regarding value for money of bortezomib?
    Franken MG; Gaultney JG; Blommestein HM; Huijgens PC; Sonneveld P; Redekop WK; Uyl-de Groot CA
    Value Health; 2014 Mar; 17(2):245-53. PubMed ID: 24636383
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Direct hospital resource utilization and costs of treating patients with multiple myeloma in Southwest Sweden: a 5-year retrospective analysis.
    Ghatnekar O; Alvegård T; Conradi N; Lenhoff S; Mellqvist UH; Persson U; Löthgren M
    Clin Ther; 2008 Sep; 30(9):1704-13. PubMed ID: 18840377
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Disease control in patients with relapsed and/or refractory multiple myeloma: what is the optimal duration of therapy?
    Ludwig H; Sonneveld P
    Leuk Res; 2012 Nov; 36 Suppl 1():S27-34. PubMed ID: 23176721
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost effectiveness of treatments for relapsed/refractory multiple myeloma: response to a methodology. RE: Hornberger J, Rickert J, Dhawan R, Liwing J, Aschan J, Löthgren M. The cost effectiveness of bortezomib in relapsed/refractory multiple myeloma: Swedish perspective. European Journal of Haematology 2010; 85 (6):484-491.
    Ishak J; Rodrigues F
    Eur J Haematol; 2011 Jul; 87(1):95; author reply 96-7. PubMed ID: 21692852
    [No Abstract]   [Full Text] [Related]  

  • 12. Cutaneous adverse reactions linked to targeted anticancer therapies bortezomib and lenalidomide for multiple myeloma: new drugs, old side effects.
    Patrizi A; Venturi M; Dika E; Maibach H; Tacchetti P; Brandi G
    Cutan Ocul Toxicol; 2014 Mar; 33(1):1-6. PubMed ID: 23638756
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of multiple myeloma: 2009 update.
    Prescrire Int; 2009 Dec; 18(104):263-6. PubMed ID: 20025098
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pomalidomide for multiple myeloma.
    Fouquet G; Bories C; Guidez S; Renaud L; Herbaux C; Javed S; Facon T; Leleu X
    Expert Rev Hematol; 2014 Dec; 7(6):719-31. PubMed ID: 25265911
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of relapsed and refractory myeloma.
    Kaufman J; Gleason C; Lonial S
    Curr Hematol Malig Rep; 2009 Apr; 4(2):99-107. PubMed ID: 20425421
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Similar efficacy of thalidomide- and bortezomib-based regimens for first relapse of multiple myeloma.
    Krejci M; Gregora E; Straub J; Minarik J; Scudla V; Adam Z; Krivanova A; Pour L; Zahradova L; Buchler T; Mayer J; Hajek R
    Ann Hematol; 2011 Dec; 90(12):1441-7. PubMed ID: 21380511
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature.
    Badros A; Goloubeva O; Dalal JS; Can I; Thompson J; Rapoport AP; Heyman M; Akpek G; Fenton RG
    Cancer; 2007 Sep; 110(5):1042-9. PubMed ID: 17654660
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bortezomib in multiple myeloma.
    Cecchi M; Caccese E; Messori A
    N Engl J Med; 2005 Sep; 353(12):1297-8; author reply 1297-8. PubMed ID: 16177258
    [No Abstract]   [Full Text] [Related]  

  • 19. (Bortezomib plus lenalidomide/thalidomide)- vs. (bortezomib or lenalidomide/thalidomide)-containing regimens as induction therapy in newly diagnosed multiple myeloma: a meta-analysis of randomized controlled trials.
    Wang A; Duan Q; Liu X; Ding K; Han Y; Zhu W; Cai X; Wu J; Sun Z
    Ann Hematol; 2012 Nov; 91(11):1779-84. PubMed ID: 22773209
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A prospective, international phase 2 study of bortezomib retreatment in patients with relapsed multiple myeloma.
    Petrucci MT; Giraldo P; Corradini P; Teixeira A; Dimopoulos MA; Blau IW; Drach J; Angermund R; Allietta N; Broer E; Mitchell V; Bladé J
    Br J Haematol; 2013 Mar; 160(5):649-59. PubMed ID: 23293914
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.